Condition
Lung Adenocarcinoma Metastatic
Total Trials
6
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (1)
P 2 (3)
Trial Status
Completed3
Recruiting2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07161713Not ApplicableRecruiting
SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors
NCT06756035Phase 1Recruiting
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT03345810Phase 2Completed
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
NCT03044626Phase 2Completed
Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
NCT02975752CompletedPrimary
EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA
NCT02946359Phase 2UnknownPrimary
A+C in Metastatic Lung Adenocarcinoma Cancer
Showing all 6 trials